AIM ImmunoTech (AIM) News Today → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free AIM Stock Alerts $0.40 +0.01 (+2.54%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 11:28 PM | markets.businessinsider.comBuy Rating Affirmed: AIM ImmunoTech’s Ampligen Shows Promising Oncology Pipeline ProgressMay 17 at 8:27 AM | finance.yahoo.comQ1 2024 AIM ImmunoTech Inc Earnings CallMay 17 at 8:27 AM | msn.comAIM ImmunoTech Inc. (AMEX:AIM) Q1 2024 Earnings Call TranscriptMay 16 at 9:13 PM | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 16 at 1:07 PM | investorplace.comAIM Stock Earnings: AIM ImmunoTech Misses EPS for Q1 2024May 16 at 7:30 AM | globenewswire.comAIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 15, 2024 | msn.comAIM ImmunoTech Q1 2024 Earnings PreviewMay 9, 2024 | globenewswire.comAIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and WebcastMay 8, 2024 | insidertrades.comAIM ImmunoTech Inc. (NYSE:AIM) COO Peter W. Rodino III Buys 30,865 SharesMay 6, 2024 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®May 6, 2024 | baystreet.caAIM Completes Ampligen TurnoutMay 6, 2024 | globenewswire.comAIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®April 29, 2024 | globenewswire.comAIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic CancerApril 25, 2024 | globenewswire.comAIM ImmunoTech Announces Release of the Next CEO Corner SegmentApril 15, 2024 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID ProgramsApril 15, 2024 | globenewswire.comAIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID ProgramsApril 11, 2024 | globenewswire.comAIM ImmunoTech Announces Release of the Next CEO Corner SegmentApril 10, 2024 | markets.businessinsider.comAim ImmunoTech Announces Positive Data From Ampligen Study In Combination With PembrolizumabApril 10, 2024 | globenewswire.comAIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian CancerApril 5, 2024 | ca.news.yahoo.comNearly 600 cars recovered in sweeping auto theft crackdown in Ontario, Quebec: policeApril 4, 2024 | investing.comEarnings call: AIM ImmunoTech optimistic on Ampligen's future in oncologyApril 3, 2024 | insidermonkey.comAIM ImmunoTech Inc. (AMEX:AIM) Q4 2023 Earnings Call TranscriptApril 2, 2024 | finance.yahoo.comQ4 2023 AIM ImmunoTech Inc Earnings CallApril 2, 2024 | markets.businessinsider.comAIM Stock Earnings: AIM ImmunoTech Misses EPS, Beats Revenue for Q4 2023April 2, 2024 | globenewswire.comAIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 28, 2024 | globenewswire.comAIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor ConferenceMarch 26, 2024 | globenewswire.comAIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and WebcastMarch 25, 2024 | globenewswire.comAIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer ResearchMarch 23, 2024 | insidertrades.comAIM ImmunoTech Inc. (NYSE:AIM) Director Purchases $15,000.18 in StockMarch 22, 2024 | globenewswire.comAIM ImmunoTech Announces Release of the Next CEO Corner SegmentMarch 20, 2024 | globenewswire.comAIM ImmunoTech Announces Release of the Next CEO Corner SegmentMarch 19, 2024 | insidertrades.comAIM ImmunoTech Inc. (NYSE:AIM) COO Peter W. Rodino III Buys 37,879 SharesMarch 15, 2024 | globenewswire.comAIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM OpportunityMarch 9, 2024 | investing.comAIM ImmunoTech launches CEO Corner for direct stakeholder engagementMarch 7, 2024 | globenewswire.comAIM ImmunoTech Announces Launch of CEO Corner PlatformFebruary 29, 2024 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business UpdateFebruary 29, 2024 | globenewswire.comAIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business UpdateFebruary 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for AIM ImmunoTech Amidst Promising Trials and Product Pipeline DevelopmentsFebruary 15, 2024 | msn.comAIM ImmunoTech commences dosing in pancreatic cancer therapy trialFebruary 14, 2024 | finance.yahoo.comAIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic CancerFebruary 14, 2024 | globenewswire.comAIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic CancerFebruary 10, 2024 | msn.comAIM ImmunoTech Touts Ampligen’s Post-COVID Study SuccessFebruary 9, 2024 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen for the Treatment of Post-COVID ConditionsFebruary 8, 2024 | msn.comAIM stock dips amid mixed results for post-COVID fatigue therapyFebruary 5, 2024 | benzinga.comAIM ImmunoTech Stock (AMEX:AIM) Dividends: History, Yield and DatesFebruary 2, 2024 | finance.yahoo.comPRISM MarketView Marks World Cancer DayJanuary 26, 2024 | msn.comAIM ImmunoTech Discloses Q1 Pancreatic Cancer Program UpdateJanuary 24, 2024 | markets.businessinsider.comAIM ImmunoTech Gets Erasmus Medical Center Ethics Board Authorization For Phase 2 Study Of AmpligenJanuary 22, 2024 | finance.yahoo.comAIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic CancerJanuary 5, 2024 | finance.yahoo.comAIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Email Address CEO of Biggest AI Chipmaker Just Dropped a Bombshell… (Ad)Nvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it. Click on Adam's shiny forehead for more details. AIM Media Mentions By Week AIM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AIM News Sentiment▼-0.220.42▲Average Medical News Sentiment AIM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AIM Articles This Week▼91▲AIM Articles Average Week Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: APTO News EVAX News SNTI News ZIVO News TVGN News NKGN News COEP News GENE News BCDA News ONVO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:AIM) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBill Gates is all about this tiny $2 stockTimothy SykesCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressMan who spotted Apple at $1.49 says: “Buy These 6 AI Stocks.”InvestorPlaceForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the Markets[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsBuy this small stock before coming AI Tidal WaveChaikin AnalyticsShocking $16T Elon Musk Crypto LeakCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
